GSK: Statement - Zantac Litigation - Delaware State Court Daubert Ruling
June 01, 2024
June 01, 2024
LONDON, England, June 1 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following statement:
* * *
GSK plc (LSE/NYSE: GSK) disagrees with the ruling by the Delaware State Court and will immediately seek an appeal. The decision by the State Court contradicts the Federal Court's MDL ruling under the same legal standard, which dismissed all cases alleging five cancer types, in December 2022.
Following the 16 epidemiological studies l . . .
* * *
GSK plc (LSE/NYSE: GSK) disagrees with the ruling by the Delaware State Court and will immediately seek an appeal. The decision by the State Court contradicts the Federal Court's MDL ruling under the same legal standard, which dismissed all cases alleging five cancer types, in December 2022.
Following the 16 epidemiological studies l . . .